We are currently conducting immune deficiency studies. These studies research increasing the volume and flow rate of dosages for individuals with a primary immunodeficiency currently on Hizentra, with the hope that this new increased volume and flow rate helps individuals to lessen the amount of time spent receiving their medication. These medications are provided at absolutely no cost, with no insurance needed. You may also be reimbursed for your time and travel and will receive care from physicians affiliated with the Clinical Research Center of Alabama.

For more information on any of the following immunodeficiency clinical research studies, please contact Will O’Donnell by calling 205.209.4179 or emailing [email protected]

Investigational Treatment for primary immunodeficiency

Ages 19-75

Grifols 1902
If you take part in this study, you will receive Gamunex-C and IVIG-PEG (separately); both study products are like the drug you are currently receiving to treat your PI. The purpose for this study is to compare Immune Globulin (Human), 10%  Caprylate /Chromatography Purified, PEG process (IVIG-PEG) to a similar product known as Gamunex-C. Gamunex-C is a human immune globulin (IgG) product that is used to treat PI and other conditions.

INVESTIGATIONAL TREATMENT FOR PRIMARY IMMUNODEFICIENCY

Ages 19-75

GRIFOLS 1906
The main purpose of this study is to see if the study drug will provide subjects enough IgG in their blood to protect them against infection and to see how safe IGSC 20% is when only infused every two weeks.
If you’re interested in participating in a clinical research study at the Clinical Research Center of Alabama, call 205.209.4100 to speak with an experienced coordinator or fill out the contact form below.